Abstract
Iclaprim is under clinical development for treating acute bacterial skin and skin structure infections (ABSSSI) and nosocomial pneumonia most often due to Gram-positive bacteria, including infections due to drug-resistant bacteria. In two recent Phase III studies of patients with acute bacterial skin and skin structure infections, intravenous iclaprim 80 mg every 12 h was noninferior to dose-adjusted vancomycin. Additional studies are planned for patients with nosocomial pneumonia. Iclaprim represents an alternative for the treatment of severe skin and pulmonary infections due to Gram-positive bacteria.
Keywords:
iclaprim; pneumonia; skin.
MeSH terms
-
Administration, Intravenous
-
Anti-Bacterial Agents / administration & dosage*
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / pharmacology
-
Clinical Trials, Phase III as Topic
-
Drug-Related Side Effects and Adverse Reactions / epidemiology
-
Drug-Related Side Effects and Adverse Reactions / pathology
-
Folic Acid Antagonists / administration & dosage*
-
Folic Acid Antagonists / adverse effects
-
Folic Acid Antagonists / pharmacology
-
Gram-Negative Bacteria / drug effects
-
Gram-Positive Bacteria / drug effects
-
Humans
-
Microbial Sensitivity Tests
-
Pneumonia, Bacterial / drug therapy*
-
Pyrimidines / administration & dosage*
-
Pyrimidines / adverse effects
-
Pyrimidines / pharmacology
-
Skin Diseases, Bacterial / drug therapy*
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Folic Acid Antagonists
-
Pyrimidines
-
iclaprim